Description
Cagrilintide/Semaglutide is a powerful, once-weekly subcutaneous injection that combines the synergistic effects of two peptides—Cagrilintide, an amylin analogue, and Semaglutide, a GLP-1 receptor agonist—for enhanced appetite suppression, delayed gastric emptying, and improved glycemic control. This innovative dual therapy is designed to support significant and sustained weight loss in individuals with obesity or overweight conditions, with or without type 2 diabetes.
Key Benefits:
Dual action for superior appetite and craving reduction
Promotes satiety and reduces caloric intake
Improves insulin sensitivity and glycemic control
Once-weekly dosing for convenience and compliance
Shown in clinical trials to support substantial weight loss
Applications:
Ideal for adults seeking medical support for weight management when combined with a reduced-calorie diet and increased physical activity. Often used under medical supervision as part of a comprehensive obesity treatment program.
